Evidence map›Paper›PMID 35917044›Full record

ArticleCellular and molecular neurobiology2023

Visualizing Sphingosine-1-Phosphate Receptor 1(S1P

Ezzat Hashemi, Ezra Yoseph, Hsing-Chuan Tsai, Monica Moreno, Li-Hao Yeh, Shalin B Mehta, Mari Kono, Richard Proia, May H Han

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ezzat HashemiDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, 1201 Welch Rd, MSLS BLG P212, Stanford, CA, 94305, USA.
Ezra YosephDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, 1201 Welch Rd, MSLS BLG P212, Stanford, CA, 94305, USA.
Hsing-Chuan TsaiDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, 1201 Welch Rd, MSLS BLG P212, Stanford, CA, 94305, USA.
Monica MorenoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, 1201 Welch Rd, MSLS BLG P212, Stanford, CA, 94305, USA.
Li-Hao YehChan Zuckerberg Biohub, San Francisco, CA, USA.
Shalin B MehtaChan Zuckerberg Biohub, San Francisco, CA, USA.
Mari KonoGenetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
Richard ProiaGenetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
May H HanDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, 1201 Welch Rd, MSLS BLG P212, Stanford, CA, 94305, USA. mayhan@stanford.edu.ORCID http://orcid.org/0000-0002-0955-6641
Stanford University · USChan Zuckerberg Initiative (United States) · USNational Institute of Diabetes and Digestive and Kidney Diseases · USStanford Medicine · US

Funding

MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
Sphingolipid Biology of NeurodegenerationZIADK056016 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI PROIA, RICHARD · 2009 to 2025
$21.3M
Mouse Models of Novel Sphingolipid Biology and Disease MechanismsZIADK056014 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI PROIA, RICHARD · 2009 to 2025
$10.6M
Training Program in Adult and Pediatric RheumatologyT32AR050942 · NIAMS · STANFORD UNIVERSITY · PI LEWIS, DAVID BRAM, ROBINSON, WILLIAM H · 2005 to 2025
$6.6M
NIAID NIH HHS T32 AI007290NIAMS NIH HHS T32 AR050942NIH HHS T32 AI 7290-32
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an inflammatory-demyelinating disease of the central nervous system (CNS) mediated by aberrant auto-reactive immune responses. The current immune-modulatory therapies are unable to protect and repair immune-mediated neural tissue damage. One of the therapeutic targets in MS is the sphingosine-1-phosphate (S1P) pathway which signals via sphingosine-1-phosphate receptors 1-5 (S1P

Indexed as

Multiple SclerosisRemyelinationAnimalsbeta-ArrestinsCentral Nervous SystemCuprizoneLysophospholipidsMiceMice, Inbred C57BLOligodendrogliaReceptors, LysosphingolipidSphingosineSphingosine-1-Phosphate Receptorsbeta-ArrestinsCuprizoneLysophospholipidsReceptors, LysosphingolipidSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate ReceptorsDemyelinationGFP reporter miceMultiple sclerosisOligodendrocyteSphingosine-1-phosphate receptor 1

Identifiers

PMID35917044
PMCPMC10444542
OpenAlexW4289443390

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.